Nature Cancer

Article	Citations
Enhancing childhood cancer targetability	728
PARP11 interfer(on)es with CAR T cell efficacy	581
A macrophage-activated abscopal effect	533
An oncolytic circular RNA therapy	436
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	402
Considering molecular alterations as pan-cancer tissue-agnostic targets	346
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	340
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	307
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	303
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	262
Gut decisions in CAR T cell therapy	238
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	205
MALAT1 protects dormant tumor cells from immune elimination	196
Breaking frontiers with multidisciplinary cancer research	195
A low-coverage liquid biopsy for lung cancer	171
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	164
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	159
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study	158
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	150
Shooting for multiplexed pathology with Orion	143
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	141
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	139
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	137
The cGAS–STING pathway and cancer	136
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	132

Expanding the options for KRAS inhibition	132
Palmitate oxidation drives a pro-metastatic post-translational modification	126
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	124
A molecular glue halts RAS–MAPK signaling	122
The importance of being generous	120
Bone marrow progenitor-like cells against leukemia cure	119
Stress granules shape metabolic reprogramming and drug resistance	117
Shaping the microenvironment in peritoneal metastases	115
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	114
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	113
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	112
Determinants of resistance and response to melanoma therapy	112
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	111
Impact of context-dependent autophagy states on tumor progression	110
Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial	110
Advancing therapeutics in small-cell lung cancer	109
Sarcoma ecotypes determine immunotherapy benefit	108
Antibody avidity meets multiple myeloma	107
Thriving in diverse ecosystems	106
Innate immunity drives epithelial cell plasticity during prostate tumor formation	106
Key insights from ESMO Congress 2025	106
Inflammation meets translation in AML	98
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	98
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	95
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	94
Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial	93
Evolving landscape of nasopharyngeal carcinoma therapy	93
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	91
A comeback for checkpoint inhibition in multiple myeloma	91
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	91
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	89
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	88
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	88
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	88
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	87
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	87
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	85
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	85
Cycling back to folate metabolism in cancer	85
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	84
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	84
Multimodal data integration improves immunotherapy response prediction	83
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	83
Radioligand cancer therapy comes to the fore	83
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	83
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	81
Immunotargeting of a recurrent AML-specific neoantigen	81
Dual inhibition of EGFR and PI3K with a single drug	81
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	80
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	80

How AI agents will change cancer research and oncology	80
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	78
Building a translational cancer dependency map for The Cancer Genome Atlas	78
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	76
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	76
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	76
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics	73
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	72
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	72
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	72
Selective targeting of malignant T cells	70
Highlights from the 2025 ASCO Annual Meeting	69
AKTing on XPO1 inhibition in AML	69
Bispecific chimeric T cell receptors tackle tumor heterogeneity	68
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	68
Regional delivery of hypoxia-responsive CAR T cells improves efficacy for solid tumors	66
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	65
Mesenchymal tumor features predict response to immune-checkpoint blockade in glioblastoma	64
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	63
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	63
Advances in antibody-based therapy in oncology	63
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer	62
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	62
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	61
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	61
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	60
The tumor microenvironment’s role in the response to immune checkpoint blockade	59
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	59
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	58
Epigenetic plasticity in PDAC	58
Anything to declare?	58
An unexpected career in cancer metabolism	57
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	57
In vivo macrophage engineering for renal cancer therapy	56
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	56
Ricolinostat is not a highly selective HDAC6 inhibitor	56
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	56
Neoadjuvant immunotherapy marks a new era in oncology	56
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	56
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	55
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	55
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors	54
Myeloma evades T cell-engaging therapies	53
Clinical and translational attributes of immune-related adverse events	53
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	53
Metabolic symbiosis in pancreatic cancer	52
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	52
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	51
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	50
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	50
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	50
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	49
p53 at the crossroads of tumor immunity	49
CD8+ T cell killing of MHC class I–deficient tumors	49
CAR T cell therapy: looking back and looking forward	48
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial	48
Understanding the biology of lung cancer brain metastases	48
Masking T cell engagers mitigates on-target off-tumor activity	48
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	48
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	47
GABA shapes GBM immune responses in a sex-dependent manner	47
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p	47
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	46
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	46
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	45
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	45
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	44
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	44
Breaking the performance ceiling for neoantigen immunogenicity prediction	43
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	43
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	42
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	42
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	42
The meaning of impact	41
Leveraging translational insights toward precision medicine approaches for brain metastases	41
Communicating with respect	41
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	41
Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan	41
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	41
Artificial intelligence for prostate cancer diagnostics	41

Radiopharma pipeline builds ahead of key data	40
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	40
Near-infrared optogenetic engineering of bacteria for cancer therapy	40
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial	39
Leveraging the potential for deintensification in cancer care	39
CD4+ CAR T cells — more than helpers	39
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	38
Leptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling	38
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results	38
A 180 degree turn en route to crafting a scientific career that never goes stale	38
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	38
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	37
Cellular neighborhoods in cancer	37
Glucagon-like peptide-1 medicines and cancer	37
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	37
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	37
Commensal metabolite boosts chemotherapy	36
Disparities, aging and childhood cancer	35
The aging lung reawakens dormant tumor cells	34
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence	34
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	34
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	33
CDK10 inhibits innate sensing to constrain antitumor immunity	33
Targeting HIF-1 to treat AML	33
Fibrotic tumors tune metabolism for immune evasion	33
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	33
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	33
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis	33
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	32
The growing threat of cyberwarfare in cancer healthcare	32
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	32
Harnessing foundation models for digital pathology without re-training	32
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	32
The landscape of T cell antigens for cancer immunotherapy	32
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	32
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	32
CAR T cell therapy for multiple myeloma	32
Checking immunotoxicity risks of checkpoint blockade	31
Not a generative AI–generated Editorial	31
Author Correction: Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy	31
T cells lead the charge against solid tumors	31
The two sides of the γδ T cell coin	31
Bicarbonate transport as a vulnerability in pancreatic cancer	31